Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Matched-adjusted comparison of liso-cel versus axi-cel for the second-line treatment of R/R LBCL

Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, explains results from a matched-adjusted indirect comparison (MAIC) using data from the TRANSFORM and ZUMA-7 trials (NCT03575351; NCT03391466) to compare lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) CAR-T therapies with standard of care (SOC) in the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Efficacy with respect to complete response (CR), progression-free survival (PFS), and event-free survival (EFS), were similar for both liso-cel and axi-cel. However, Dr Abramson highlights that axi-cel had a worse toxicity profile compared to liso-cel. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BMS, Seattle Genetics: Research Funding; BMS, AbbVie, Genentech, Epizyme, BeiGene, Kymera, Bluebird Bio, Incyte, Kite Pharma, Genmab, Ono Pharma, Mustang Bio, MorphoSys, Regeneron, Century, AstraZeneca, Lilly, Janssen: Consultancy.